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ABSTRACT 
We recently found that renal carbonic anhydrase (CA) is involved in the reabsorption of 
inorganic nitrite (NO2–), an abundant reservoir of nitric oxide (NO) in tissues and cells. 
Impaired NO synthesis in the endothelium and decreased NO bioavailability in the 
circulation are considered major contributors to the development and progression of renal 
and cardiovascular diseases in different conditions including diabetes. Isolated human and 
bovine erythrocytic CAII and CAIV can convert nitrite to nitrous acid (HONO) and its 
anhydride N2O3 which, in the presence of thiols (RSH), are further converted to S-
nitrosothiols (RSNO) and NO. Thus, CA may be responsible both for the homeostasis of 
nitrite and for its bioactivation to RSNO/NO. We hypothesized that enhanced excretion of 
nitrite in the urine may contribute to NO-related dysfunctions in the renal and 
cardiovascular systems, and proposed the urinary nitrate-to-nitrite molar ratio, i.e., UNOxR, 
as a measure of renal CA-dependent excretion of nitrite. Based on results from clinical and 
experimental animal studies, here we report on a first evaluation of UNOxR. We determined 
UNOxR values in preterm neonates, healthy children and adults, in children suffering from 
type 1 diabetes mellitus (T1DM) or Duchenne muscular dystrophy (DMD), in elderly subjects 
suffering from chronic rheumatic diseases, type 2 diabetes mellitus (T2DM), coronary artery 
disease (CAD) or peripheral arterial occlusive disease (PAOD). We also determined UNOxR 
values in healthy young men who ingested isosorbide dinitrate (ISDN), pentaerythrityl 
tetranitrate (PETN), or inorganic nitrate. In addition, we tested the utility of UNOxR in two 
animal models, i.e., the LEW.1AR1-iddm rat, an animal model of human T1DM, and the 
APOE*3-Leiden.CETP mice, a model of human dyslipidemia. Mean UNOxR values were lower 
in adult patients with rheumatic diseases (187) and in T2DM patients of the DALI study (74) 
as compared to healthy elderly adults (660) and healthy young men (1500). The intra- and 
inter-variability of UNOxR was of the order of 50% in young and elderly healthy subjects. 
UNOxR values were lower in black compared to white boys (314 vs. 483, P=0.007), which is 
in line with reported lower NO bioavailability in black ethnicity. Mean UNOxR values were 
lower in DMD (424) compared to healthy (730) children, but they were higher in T1DM 
children (1192). ISDN (3×30 mg) decreased stronger UNOxR compared to PETN (3×80 mg) 
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after 1 day (P=0.046) and after 5 days (P=0.0016) of oral administration of therapeutically 
equivalent doses. In healthy young men who ingested NaNO3 (0.1 mmol/kg/d), UNOxR was 
higher than in those who ingested the same dose of NaCl (1709 vs. 369). In LEW.1AR1-
iddm rats, mean UNOxR values were lower than in healthy rats (198 vs 308) and comparable 
to those in APOE*3-Leiden.CETP mice (151).  
 
Keywords: Diabetes; Drugs; Health; Mass spectrometry; Nitric oxide reservoir; Renal 
carbonic anhydrase; Rheumatic disease 
 
Abbreviations 
ADMA  Asymmetric dimethylarginine 
AQP  Aquaporin 
BMI  Body mass index 
CA  Carbonic anhydrase 
CAD  Coronary artery disease 
CysSNO S-Nitrosocysteine 
DALI  Diabetes Atorvastatin Lipid Intervention study 
DMD  Duchenne muscular dystrophy 
FSGS  Focal segmental glomerulosclerosis 
 
GSNO   S-Nitrosoglutathione 
ISDN  Isosorbide dinitrate 
NAC  N-Acetylcysteine 
NO  Nitric oxide 
NOS  Nitric oxide synthase 
eNOS  Endothelial NOS 
iNOS  Inducible NOS 
nNOS  Neuronal NOS 
PAOD  Peripheral arterial occlusive disease 
PAR  Peak area ratio 
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PETN  Pentaerythrityl tetranitrate 
RSH  Thiols 
RSNO  S-Nitrosothiols 
T1DM  Type 1 diabetes mellitus 
T2DM  Type 2 diabetes mellitus 
UNOx  Sum of urinary nitrate and nitrite 
UNOxR  Urinary nitrate-to-nitrite molar ratio 
XOR  Xanthine oxidoreductase 
 
Introduction 
Nitric oxide (NO) possesses a wide spectrum of physiological functions that include 
regulation of blood pressure and platelet function (Moncada and Higgs 1993). Impaired NO 
synthesis, particularly in the endothelium, and decreased NO bioavailability in the 
circulation due to elevated oxidative stress are considered major contributors to the 
development and progression of renal and cardiovascular diseases and complications in 
different conditions including diabetes (Paolocci et al. 2001; Förstermann 2006; Landmesser 
et al. 2006; Heller et al. 2006). The role of the L-arginine/nitric oxide (L-Arg/NO) pathway 
(Fig. 1) and of oxidative stress in several diseases including diabetes mellitus, rheumatic 
and other autoimmune diseases has been frequently investigated. Yet, results are 
contradictory and underlying mechanisms are unresolved. Previously, we described a 
spontaneous animal model of human type 1 diabetes mellitus (T1DM), the LEW.1AR1-iddm 
rat (Lenzen et al. 2001), and demonstrated its suitability for delineating mechanisms 
involved in the development of autoimmune diabetes (Jörns et al. 2014). In the present 
study, we used this model to investigate the role of the L-Arg/NO pathway and of oxidative 
stress in the T1DM situation.  
Nitrate is a major and nitrite a minor metabolite of NO (Tsikas 2008). In addition to 
the L-Arg/NO pathway, foods, water, air and pharmaceuticals may also contribute to nitrate 
and nitrite measured in biological samples (Fig. 1). Under certain standardized conditions, 
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most notably overnight fasting, avoidance of nitrate-rich diet and use of diuretics (Sütö et 
al. 1995; Rhodes et al. 1995; Baylis and Vallance 1998; Tsikas 2015), circulating and 
urinary nitrate are useful measures of systemic and whole-body NOS activity, respectively. 
In humans, circulating nitrite is a measure of endothelial NOS (eNOS) activity (Kleinbongard 
et al. 2003, 2006). Urinary 15(S)-8-iso-prostaglandin F2α (15(S)-8-iso-PGF2α) is a biomarker 
of oxidative stress (Pham et al. 2009). In urine of patients with rheumatic diseases, nitrite 
correlated with 3-nitrotyrosine suggesting nitrite as a biomarker of nitrosative stress (Pham 
et al. 2009). Based on the sum of urinary nitrate and nitrite (UNOx) as measured by the 
Griess assay after reduction of nitrate to nitrite, previous studies in conscious rats (Sütö et 
al. 1995) and anaesthetized dogs (Godfrey and Majid 1998) indicated that urinary 
nitrate/nitrite excretion depends predominantly on tubular handling. Especially, intravenous 
administration of the carbonic anhydrase (CA) inhibitor acetazolamide to conscious rats 
increased UNOx by a factor of almost 3, strongly suggesting involvement of renal CA in the 
handling of nitrate/nitrite excretion/reabsorption (Sütö et al. 1995). In humans, we have 
recently shown that renal CA isoforms are involved in the reabsorption of inorganic nitrite 
(NO2–) and to a lesser extent of inorganic nitrate (ONO2–) (Tsikas and Chobanyan-Jürgens 
2010; Chobanyan-Jürgens et al. 2012a; Tsikas et al. 2014; Schneider et al. 2015). This 
newly discovered role of renal CA isoforms is of particular importance, because nitrite is an 
important and abundant reservoir of NO in tissues and cells including erythrocytes (Gladwin 
et al. 2006). Nitrite, but not nitrate, can be reduced to NO by several proteins and enzymes 
including hemoglobin and xanthine oxidoreductase (XOR) (Fig. 1). Furthermore, in vitro 
isolated bovine erythrocytic CAII treated with the CA inhibitors dorzolamide and 
acetazolamide has been reported to enhance NO formation from nitrite (Aamand et al. 
2009). However, we (Hanff et al. 2015; Zinke et al. 2015) and others (Andring et al. 2018) 
found that CAII and CAIV do not reduce nitrite to NO in the presence or absence of 
dorzolamide or acetazolamide. We demonstrated that human and bovine CA isoforms can 
convert nitrite into S-nitrosoglutathione (GSNO) and S-nitrosocysteine (CysSNO) (Hanff et 
al. 2015; Zinke et al. 2015). GSNO and CysSNO possess NO-related biological activities 
including vasodilation and inhibition of platelet aggregation (Fig. 1). CysSNO is a potent NO 
AMAC 
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donor and a strong inhibitor of platelet aggregation acting via cGMP-dependent and cGMP-
independent mechanisms (Tsikas et al. 1999). CysSNO and GSNO are potent endogenous 
S-nitrosylating species.  
The CA inhibitor acetazolamide was found to increase the excretion of nitrite in 
healthy humans at oral therapeutic doses (5 mg/kg), suggesting a role of renal CA in the 
reabsorption of nitrite (Chobanyan-Jürgens et al. 2012a) (Fig. 1). We also found that N-
acetylcysteine (NAC) increased nitrite and nitrate excretion in the urine, suggesting that 
NAC is an inhibitor of renal CA isoforms (Tsikas et al. 2014). In vitro, paracetamol 
(acetaminophen) has been shown to inhibit the CO2 hydration activity of several human CA 
isozymes (Ki range, 4 µM to 800 µM) (Innocenti et al. 2008).  
In consideration of the potential role of renal CA isoforms in maintaining NO 
homeostasis, we hypothesized that enhanced excretion of nitrite in the urine may be an 
additional, not yet considered factor affecting NO homeostasis in the circulation. We 
recently proposed the urinary nitrate-to-nitrite molar ratio UNOxR as a measure of renal CA-
dependent reabsorption of urinary nitrite in humans (Schneider et al. 2015) (Fig. 1). The 
whole-body NO synthesis can be expressed as the sum of the concentration of nitrate and 
nitrite in urine: [NO] = [nitrate]U + [nitrite]u. Because [nitrate]U is much higher than 
[nitrite]u in non-infected urine, and urinary nitrate’s reabsorption is only marginally 
dependent upon renal CA isoforms (see below), whole-body NO synthesis can be expressed 
in approximation solely by the urinary excretion of nitrate: [NO] ≈ [nitrate]U. In contrast, 
urinary nitrite is reabsorbed in the kidney mainly by a mechanism involving renal CA 
isoforms (Tsikas and Chobanyan-Jürgens 2010; Chobanyan-Jürgens et al. 2012a; Tsikas et 
al. 2014; Schneider et al. 2015). In theory, the concentration of nitrite in the urine could be 
used as a measure of a nitrite-dependent renal CA activity. However, as nitrate and nitrite 
cannot be considered independent of each other, we divided the [nitrate]U by the [nitrite]U 
and proposed the formula UNOxR = [nitrate]U/[nitrite]u to estimate CA-dependent 
reabsorption of nitrite in the kidney. High UNOxR values would express high nitrite 
reabsorption and thus high CA activity. Low UNOxR values would express low nitrite 
reabsorption and low CA activity.  
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In the present study, we determined the UNOxR in LEW.1AR1-iddm rats (i.e., model of 
T1DM), in APOE*3-Leiden.CETP mice (i.e., model of dyslipidemia), in adults with type 2 
diabetes mellitus (T2DM), in adults suffering from rheumatic diseases, peripheral artery 
occlusive disease (PAOD) or coronary artery disease (CAD), in healthy adults and in healthy 
young black and white boys. The T1DM and T2DM animal models are discussed in more 
detail in the next section. We also determined the UNOxR in healthy young subjects before 
and after oral intake of therapeutically equivalent doses of the organic nitrates isosorbide 
dinitrate (ISDN) or pentaerythrityl tetranitrate (PETN), which are known to be metabolized 
to inorganic nitrite and nitrate which are found both in blood and in urine (Keimer et al. 
2003) (Fig. 1). The baseline data reported and discussed in the present paper are 
summarized in Table 1. The potential utility and limitations of UNOxR in experimental and 
clinical studies are discussed. Eventually, we address the presumably CA-dependent 
bioactivation of inorganic nitrite to potential mutagenic and cancerogenic nitrosamines such 
as N-nitrososarcosine (Fig. 1). 
 
 
Methods 
 
Human studies 
 
UNOxR in healthy subjects who took acetazolamide 
Acetazolamide is a strong CA inhibitor (IC50 0.1 µM with respect to esterase activity). A 44-
years old healthy male volunteer took orally acetazolamide (a 500-mg Diamox retard 
capsule, Goldshield Pharmaceuticals Ltd, U.K.) according to previously reported studies 
(Tsikas and Chobanyan-Jürgens 2010; Chobanyan-Jürgens et al. 2012a). The volunteer did 
not take any drugs in the preceding two weeks and was not fasting overnight, but 
restrained from nitrite/nitrate-rich foods and beverages for 12 h before and during the 
study. In the morning (8 a.m.), the volunteer was given orally one capsule acetazolamide 
AMAC 
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corresponding to a dose of about 5 mg/kg bodyweight. First, the volunteer emptied his 
bladder and collected the first urine specimen. Immediately after collection of the 0-h urine 
sample, acetazolamide was taken with 200 mL of drinking water. Urine samples were 
collected in polypropylene tubes which were immediately closed, put on ice and the urine 
pH was measured. Then urine samples were aliquoted in 1-mL proportions and carbonate 
was measured at the same day. Nitrite, nitrate and creatinine were measured on next day 
after thawing the samples which had been stored at -20 °C. Fresh and thawed urine 
samples were centrifuged (800×g, 4 °C, 5 min) before analytical measurements. 
 
UNOxR in healthy young men and effects of organic nitrates 
In a previous randomized, double-blind, crossover study (Keimer et al. 2003), 18 healthy 
non-obese young men (mean age, 26 years) collected urine samples for 24 hours at 
baseline and 1 and 5 days after daily oral administration of therapeutically relevant doses of 
isosorbide dinitrate (ISDN, 3×30 mg per day) or pentaerythrityl tetranitrate (PETN, 3×80 
mg per day) with an in-between interval of three weeks. By using the previously measured 
urinary nitrate and nitrite concentrations (Keimer et al. 2003) we calculated the UNOxR 
values before (day 0) and after drug ingestion (day 1 and day 5) (see Table 1).  
 
Effects of beta-blockers on UNOxR in healthy young men  
In a previous double-blind, randomized, cross-over study (Fahlbusch et al. 2004), 17 
healthy men received antihypertensive doses of the beta-blockers carvedilol (25 mg b.i.d.), 
metoprolol (100 mg b.i.d.) or placebo for 6 days. The previously measured urinary nitrate 
and nitrite concentrations (Fahlbusch et al. 2004) were used to calculate the UNOxR values 
before (day 0) and after drug ingestion (see Table 1). 
 
UNOxR in hypogonadal men and effects of testosterone treatment  
Previously (Leifke et al. 2008, Tsikas and Kinzel 2017), we investigated the effects of 
normalization of plasma testosterone levels in ten hypogonadal men on plasma levels and 
urinary excretion of asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor 
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(Tsikas 2008). In urine samples of eight men of that study the concentration of nitrate and 
nitrite was determined and the UNOxR values were calculated (see Table 1).  
 
 
UNOxR in healthy elderly subjects and patients suffering from rheumatic diseases 
By using the measured urinary nitrate and nitrite concentrations of a previously reported 
study (Pham et al. 2009) we calculated the UNOxR values in healthy subjects (n=41; 16 
women, 25 men; mean age, 47 years) and in patients with chronic rheumatic diseases 
(n=27; 18 women, 10 men; mean age, 55 years) (see Table 1). 
 
UNOxR in humans suffering from T2DM 
The Diabetes Atorvastatin Lipid Intervention (DALI) study is a randomised double-blind, 
placebo-controlled, multicentre parallel-group study on 217 patients with T2DM and diabetic 
dyslipidemia conducted in the Netherlands (The DALI Study Group 2001). In T2DM patients 
who did not receive atorvastatin we measured the urinary excretion of nitrate and nitrite 
and calculated the UNOxR values. Patients’ age and diabetes duration were (mean±SD) 
59.6±7.7 years and 10.1±7.5 years, respectively (Tsikas et al. 2015) (see Table 1). 
 
UNOxR in preterm neonates  
Previously (Buck et al. 2017), we measured urinary nitrate and nitrite concentrations in 
preterm neonates (34 girls, 42 boys) with a gestational age of 23+6 to 36+1 weeks and 
calculated the UNOxR values (Table 1). 
 
UNOxR in healthy black and white boys from South Africa 
Cardiovascular disease occurs earlier in black ethnicity than in white counterparts (Schutte 
et al. 2017). We designed a study to include children at the earliest possible age whereby 
the child themselves had the choice of study participation. Female sex was excluded due to 
potential early onset menses and hormonal influences. The age range of 6-8 years was 
selected and children were recruited from the foundation phase in pre-primary and primary 
AMAC 
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schools. The selection was made in schools with demographically equal black and white 
ethnicity and to account for socioeconomic comparison. In this study, we found that black 
boys have a compromised vasculature in terms of increased arterial stiffness, diastolic blood 
pressure, and carotid wall thickness and advanced glycation end products (Mokwatsi et al. 
2017). We hypothesized that the measurement of UNOxR values in these black and white 
boys would contribute to a better understanding of the early onset of cardiovascular ageing 
in black ethnicity. In urine samples collected previously we newly determined nitrate, nitrite 
and creatinine concentrations as described previously (Hanff et al. 2017) and calculated the 
UNOxR values (Table 1). 
 
 
Animal studies 
 
UNOxR in the LEW.1AR1-iddm rat as model of human T1DM 
Diabetes manifested in the animals (n=5) at day 66±4 of life with an average blood glucose 
concentration of 14.8±1.3 mM. Thereafter, a chronic diabetic metabolic state was 
maintained for around 4 months (109±14 days) during which blood glucose values were 
maintained within a range of 13-23 mM through insulin supplementation by implantation of 
a slow-release insulin pellet (Linplant®, Lin Shin Canada Ltd, Toronto, Canada). In urine 
samples collected from these chronically diabetic rats (blood glucose, 18.1±2.7 mM; n=5) 
and non-diabetic control rats (blood glucose, 5.1±2.7 mM; n=5) of either sex, we 
determined representative biomarkers of the L-Arg/NO pathway, i.e., nitrite, nitrate, UNOxR, 
and ADMA, as well as the oxidative stress biomarker 15(S)-8-iso-PGF2α. Creatinine excretion 
during the same period of time did not differ between the groups (1.42±0.22 vs 1.36±0.41 
µmol, P=0.916). All data reported above are given as mean±SD. Biomarker urinary 
excretion rates in this and in the other studies described in this work were corrected for 
creatinine excretion and are expressed as nmol or µmol analyte per mmol creatinine.  
 
UNOxR in APOE*3-Leiden.CETP mice 
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The APOE*3-Leiden.CETP mice are a well-established mouse model for familial 
dysbetalipoproteinemia with human-like lipoprotein metabolism and atherosclerosis 
development which respond in a human-like manner to both lipid-lowering and HDL-raising 
drugs like statins, fibrates and niacin used in the treatment of cardiovascular diseases 
(Zadelaar et al. 2007; van der Hoogt et al. 2007; van der Hoorn et al. 2008; de Haan et al. 
2008; Westerterp et al. 2006). We determined urinary nitrate and nitrite concentrations and 
calculated the UNOxR values in urine samples of a previously reported study (Berbée et al. 
2013) in dyslipidemic female APOE*3-Leiden.CETP mice treated with resveratrol, 
atorvastatin or with a combination of resveratrol and atorvastatin.  
In a second APOE*3-Leiden.CETP mice study, we investigated the effect of oral 
gavage of ritonavir (ritonavir, 60 mg/kg/d) alone and in combination with lopinavir 
(lopinavir/ritonavir, 40/10 mg/kg/d), of atazanavir (60 mg/kg/d) or placebo (vehicle PEG-
400) for 16 days. Pooled urine samples from 2-3 mice in metabolic cages were collected 
during the night at three different time points during the study. 
The experiments in APOE*3-Leiden.CETP mice were approved by the Institutional 
Animal Care and Use Committee of The Netherlands Organization for Applied Research 
(TNO). 
 
Analytical methods 
The concentrations of nitrite, nitrate, ADMA, 15(S)-8-iso-PGF2α, creatinine and bicarbonate 
in urine samples of the studies described in this work were determined by previously 
reported fully validated GC-MS and GC-MS/MS methods (Tsikas 2000; Tsikas et al. 2003a, 
b, 2010; Hanff et al. 2017). In the human studies and where possible in the animal studies 
reported in the present work, precautions were taken to prevent both loss of nitrite and 
artefactual formation of nitrite from nitrate by bacterial nitrate reductases. These 
precautions included avoidance of urine acidification, storage of urine during collection in a 
refrigerator at 4 – 8 °C, and storage at -20 °C until analysis. For collection of human urine 
over 24 h polypropylene bottles containing 1 mM each of 4-hydroxy-TEMPO and EDTA were 
used as radical and metal ions scavengers, respectively.  
AMAC 
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Statistical analyses 
Data are presented as mean±SD, mean±SEM or median [25th-75th interquartile] as 
indicated in the text. Statistical analysis was performed using the Mann-Whitney test (and 
unpaired t-test for unpaired analysis) and the Wilcoxon test (and paired t-test for paired 
analysis). If not otherwise stated Spearman correlation was performed. Statistical 
significance was assumed for P<0.05. Data analysis was performed using GraphPad Prism 
5. 
 
Results 
The results of the studies reported and discussed in the present work are summarized in 
Table 1 and presented in the Figures that follow. 
 
Human studies 
 
UNOxR in healthy subjects taken acetazolamide 
In the urine samples, the concentration of nitrate, nitrite and carbonate changed 
concomitantly upon ingestion of the CA inhibitor acetazolamide (Fig. 2A). In the time 
window of 0 – 3 h with maximum inhibition of CA activity, there were close correlations 
between carbonate and nitrite (Spearman r=0.893, P=0.012), and between nitrate and 
nitrite (r=0.857, P=0.024), while the correlation between carbonate and nitrate failed 
barely statistical significance (r=0.75, P=0.066). The urinary excretion of nitrate and nitrite 
and the UNOxR value correlated with the pH value of the urine samples (Fig. 2B-D). Urinary 
nitrate (r=0.991) and nitrite (r=0.998) increased moderately and linearly with increasing 
urinary pH until the value of 7.31. In the very narrow pH range of 7.38 to 7.45, urinary 
nitrate decreased suddenly and linearly (r=-0.974), while urinary nitrite increased abruptly 
and linearly (r=0.922). In this pH range, the UNOxR value decreased also suddenly (Fig. 2D). 
Considering the entire time window (24 h), the UNOxR value correlated inversely with the 
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creatinine-corrected excretion of carbonate (r=-0.955, P<0.0001) and nitrite (r=-1.000, 
P<0.0001). UNOxR correlated inversely with the urinary pH (r=-0.997, P<0.0001), whereas 
creatinine-corrected nitrate excretion did not correlate with UNOxR (r=-0.358, P=0.313). 
These observations suggest that UNOxR is a useful parameter to measure renal CA-
dependent nitrite reabsorption in humans (see Fig. 1).  
 
Effects of organic nitrates on UNOxR in healthy young men  
In 18 healthy non-medicated young men of a previously reported study (Keimer et al. 
2003), the baseline UNOxR values varied by about 60%, but the average baseline UNOxR 
value did not differ significantly on day 1 and day 21 (P=0.371; Fig. 3A). The baseline 
creatinine-corrected nitrate and nitrite excretion rates were (mean±SEM) 97.6±13.2 
µmol/mmol and 74.3±9.3 nmol/mmol on day 1, and 109±22 µmol/mmol and 127±38 
nmol/mmol on day 21, respectively (Table 1). At baseline, creatinine-corrected excretion of 
nitrite and nitrate did not correlate with each other in the PETN and ISDN groups (r=0.362, 
P=0.139 and r=0.257, P=0.303, respectively). Creatinine-corrected excretion of nitrite (r=-
0.694, P=0.001 and r=-0.598, P=0.009) but not of nitrate (r=0.352, P=0.152 and r=0.416, 
P=0.086) did correlate with UNOxR in the PETN and ISDN groups, respectively. Intake of 
PETN or ISDN resulted in decreases of the UNOxR values (Fig. 3B). Thus, the UNOxR values 
were (mean±SEM) 1570±233 at baseline and decreased to 801±132 after 1 day and to 
599±44 after 5 days of PETN administration. The UNOxR values were (mean±SEM) 
1403±188 at baseline and decreased to 483±66 after 1 day and to 383±30 after 5 days of 
ISDN administration (Table 1). For PETN and ISDN the UNOxR values between baseline and 
day 1 (P=0.004 and P=0.0002, respectively) or day 5 (P=0.0005 and P<0.0001, 
respectively) were statistically significantly different (two-tailed paired t test). For both 
drugs the differences were not significant when comparing day 1 with day 5 of drug 
administration. The UNOxR values did not differ between the two groups (P=0.681) at 
baseline, but UNOxR values did significantly differ after 1 day (P=0.046) and after 5 days 
(P=0.002) of treatment. These observations indicate that both, PETN and ISDN, affected 
the renal CA-dependent nitrite excretion in the healthy young men at the doses used.  
AMAC 
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Effects of beta-blockers on UNOxR in healthy young men  
In 15 healthy non-medicated young men of a previously reported study (Fahlbusch et al. 
2004), the creatinine-corrected nitrate excretion rates were (mean±SEM) 90.5±15.6 
µmol/mmol in the placebo group (Table 1), 57.6±9.7 µmol/mmol in the metoprolol group 
and 62.2±15.4 µmol/mmol in the carvedilol group. The corresponding creatinine-corrected 
nitrite excretion rates were 291±55.4 nmol/mmol (Table 1), 193.9±25.4 nmol/mmol and 
243.9±43.8 nmol/mmol. The calculated UNOxR values in the placebo group (406±61) (Table 
1) did not differ from those in the metoprolol group (358±67, P=0.54) and the carvedilol 
group (314±52, P=0.42). These observations suggest that neither metoprolol nor carvedilol 
affected the renal CA-dependent reabsorption of nitrite in the healthy young men at the 
therapeutical doses used.  
 
Relationship between UNOxR and blood pressure in PAOD  
Nitrite is reabsorbed in the kidneys in part due to renal CA activity. We proposed the urinary 
nitrate-to-nitrite molar ratio UNOxR as a measure of this type of CA activity and NO 
bioavailability in the circulation (Fig. 1). Loss of nitrite, an abundant reservoir of NO in the 
circulation (Gladwin et al. 2006), may contribute to the development and/or progression of 
NO-related cardiovascular dysfunction in various diseases. Strong supporting evidence of 
this provides our observation that at baseline both systolic and diastolic pressure values 
correlate inversely with the UNOxR values measured in 40 PAOD patients divided into two 
groups consisting each of 20 patients (Schneider et al. 2015) (Fig. 4). Considering the 
baseline values of the whole collective, creatinine-corrected excretion of nitrate and nitrite 
correlated with each other (r=0.481, P=0.002). UNOxR correlated inversely with the 
creatinine-corrected excretion of nitrite (r=-0.713, P<0.0001), but did not correlate with 
creatinine-corrected excretion of nitrate (r=0.150, P=0.357). In the ARG group (patients 
received orally L-arginine for three months), creatinine-corrected excretion of nitrite 
correlated inversely with UNOxR at baseline (r=-0.862, P<0.0001) and after treatment (r=-
0.578, P=0.0076). In the ARG group, creatinine-corrected excretion of nitrate did not 
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correlate with UNOxR at baseline (r=0.045, P<0.85) and after treatment (r=0.311, 
P=0.1814). In the PLA group (patients received orally mannitol for three months), 
creatinine-corrected excretion of nitrite correlated inversely with UNOxR at baseline (r=-
0.643, P=0.0022) and after treatment (r=-0.891, P<0.0001). In the PLA group, creatinine-
corrected excretion of nitrate did not correlate with UNOxR at baseline (r=0.404, P=0.0774), 
but did correlate positively after treatment (r=0.681, P=0.001). L-Arginine supplementation 
to the PAOD patients (ARG group) for three months did not change UNOxR (461 [311-678] 
vs. 545 [311-594] P=0.858). Also, placebo (mannitol) supplementation to the PAOD 
patients (PLA group) for three months did not result in considerable decrease in UNOxR (342 
[266-498] vs. 316 [157-441] P=0.409). UNOxR did not differ in the groups at baseline 
(P=0.1632), but did differ after treatment with L-arginine or placebo (P=0.024). 
 In a similar study, 60 patients suffering for CAD were treated with L-arginine (ARG 
group, n=31) or mannitol as placebo (PLA group, n=29) for three and six months 
(Schneider et al. 2015) (Table 1). Considering all data points available (n=168), creatinine-
corrected excretion of nitrite correlated positively with the creatinine-corrected excretion of 
nitrate (r=0.457, P<0.0001) and inversely with UNOxR (r=-0.777, P<0.001). Creatinine-
corrected excretion of nitrate failed to correlate with UNOxR (r=0.143, P=0.064). In the PLA 
group, UNOxR decreased considerably after three and six months (409 [237-777] vs. 273 
[121-438] P=0.0036 and 273 [154-361] P=0.0028, respectively). In the ARG group, UNOxR 
did not change after three and six months (406 [225-708] vs. 430 [250-570] P=0.495 and 
vs. 300 [217-447] P=0.284, respectively). Obviously, L-arginine supplementation avoided a 
decrease of UNOxR over three and six months.  
 In the PAOD and CAD studies, patients received orally either L-arginine or mannitol 
at high dosages (Schneider et al. 2015). L-Arginine, D-arginine and mannitol are known to 
act on the proximal tubule and to affect bicarbonate reabsorption (DuBose and Lucci 1983; 
Battle and Chan 1989; Sütö et al. 1995). The PAOD and CAD patients of our studies 
suffered from additional diseases including diabetes mellitus, and they received chronically 
many drugs including organic nitrates. Although oral bioavailability of mannitol and its 
subsequent excretion in urine are relatively low (Sequeira et al. 2012), the situation in the 
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PAOD and CAD studies is very complex and nitrite-reabsorption may have been affected by 
many different factors in the patients (see also below).     
  
UNOxR in hypogonadal men and effects of testosterone treatment  
In the urine samples of eight hypogonadal men of a previously reported study (Leifke et al. 
2008), the baseline creatinine-corrected nitrate and nitrite excretion rates were determined 
to be 66.5 [53.6-84.5] µmol/mmol and 0.56 [0.41-0.75] µmol/mmol, respectively; the 
corresponding UNOxR value was calculated to be 123±33 (Tsikas and Kinzel 2017; Table 1). 
These baseline UNOxR levels are low, indicating impaired renal CA-dependent reabsorption of 
nitrite in the hypogonadal men. At baseline, UNOxR correlated positively with plasma 
testosterone (r=0.72, P=0.044) (Tsikas and Kinzel 2017). After pharmaceutical 
normalization of plasma testosterone levels with transdermal testosterone, the creatinine-
corrected nitrate and nitrite excretion rates were lower, i.e., 49.8 [41.1-58.6] µmol/mmol 
and 0.31 [0.19-0.55] nmol/mmol, respectively. The corresponding UNOxR value was 
calculated to be 156±60. Yet, the decreases in nitrate (P=0.065) and nitrite excretion 
(P=0.141) and the increase in UNOxR were not statistically different (P=0.505). Before and 
after testosterone treatment, creatinine-corrected excretion of nitrate and nitrite correlated 
with each other (r=0.832, P=0.01 and r=0.858, P=0.006, respectively). At baseline, 
creatinine-corrected excretion of nitrate and nitrite correlated inversely with UNOxR: r=-
0.680, P=0.063 and r=-0.891, P=0.003, respectively. After treatment, creatinine-corrected 
excretion of nitrate and nitrite correlated inversely with UNOxR: r=-0.660, P=0.075 and r=-
0.867, P=0.005, respectively. These correlations did not change when considering all data 
together: r=0.855, P<0.0001 for nitrate vs. nitrite; r=-0.654, P=0.006 for nitrate vs. 
UNOxR; and r=-0.836, P<0.0001 for nitrite vs. UNOxR. Interestingly, the UNOxR values 
correlated inversely with the creatinine-corrected urinary excretion of ADMA (Tsikas and 
Kinzel 2016), both at baseline (r=-0.71, P=0.049) and after testosterone treatment (r=-
0.75, P=0.032). 
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UNOxR in healthy non-medicated elderly subjects and in patients suffering from 
rheumatic diseases  
As reported earlier (Pham et al. 2009), patients with rheumatic diseases were found to have 
higher creatinine-corrected excretion rates of nitrite (1100±300 vs. 190±20 nmol/mmol) 
but not of nitrate (105±13 vs 106±12 µmol/mmol, P=0.80) when compared to healthy 
subjects of comparable age (Table 1). To evaluate potential biological variation and 
differences in gender and age, we determined the UNOxR values in a group of middle-aged 
healthy non-medicated men and women of a previously reported study (Pham et al. 2009). 
In 41 healthy subjects (16 females, 25 males; mean age, 47 years; range, 26 – 82 years), 
the UNOxR values did not differ (P=0.455) between men and women (mean±SD): 605±348 
vs. 663±367 (Fig. 5A), but varied considerably within the groups by 58% and 55%, 
respectively. The UNOxR values of the whole group ranged between 166 and 1577 
(mean±SD, 626±351) and varied on average by 56%. In this population, there was no 
correlation between the UNOxR values and the pH values of the urine samples (Fig. 5B) or 
age of the subjects (Fig. 5C). Patients with chronic rheumatic diseases had statistically 
significantly lower UNOxR values as compared to the middle-aged healthy subjects 
(mean±SEM; 187±22 vs. 660±72, P<0.0001), suggesting impaired renal CA-dependent 
excretion of nitrite in chronic rheumatic diseases. Among the rheumatic patients, the lowest 
UNOxR values were observed in those suffering from rheumatoid arthritis (138±34, n=10) 
and the highest in patients with undifferentiated arthritis (230±34, n=10); the difference 
between these subgroups did not reach statistical significance (Mann-Whitney test, 
P=0.089). Creatinine-corrected excretion of nitrate and nitrite correlated with each other in 
the rheumatic patients (r=0.379, P=0.047) and in the healthy subjects (r=0.335, P=0.032). 
UNOxR correlated more closely with the creatinine-corrected excretion of nitrate in the 
healthy subjects (r=0.608, P<0.0001 vs. r=0.340, P<0.0001 in patients), as well as with 
the creatinine-corrected excretion of nitrite in the patients (r=-0.612, P=0.001 vs. r=-
0.479, P=0.002 in healthy subjects). 
 
UNOxR in human type 2 diabetes mellitus  
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T2DM patients excrete considerably higher nitrate (on average 129 to 162 µmol/mmol 
creatinine) and nitrite (on average 2.3 to 3.9 nmol/mmol creatinine) amounts in the urine 
than healthy subjects (Tsikas et al. 2015). We calculated the UNOxR values using the urinary 
nitrate and nitrite concentrations measured in the previously reported study. We also 
investigated potential correlations between UNOxR and age, disease duration or inflammation 
markers, as well as the effects of the lipid-lowering drug atorvastatin in the T2DM patients 
in the DALI study (Tsikas et al. 2015). 
 UNOxR values were (mean±SEM) only 68.3±3.8 at baseline in the T2DM patients of 
the DALI study, indicating severely impaired CA-dependent nitrite reabsorption in the T2DM 
patients (Table 1). There was no correlation between UNOxR and age or diabetes duration 
(Fig. S1A, B; see Supplement). Creatinine-corrected excretion of nitrate and nitrite 
correlated with each other in the T2DM patients (r=0.322, P<0.0001). UNOxR correlated 
more closely with the creatinine-corrected excretion of nitrite (r=-0.610, P<0.0001) than of 
nitrate (r=-0.495, P<0.0001). At baseline, urinary nitrite and nitrate excretion and UNOxR 
did not correlate with the inflammation markers TNF, IL-1, CRP (data not shown). 
Treatment of the T2DM patients with atorvastatin (10 mg/day or 80 mg/d) for 30 weeks did 
not result in changes of UNOxR (Fig. S1C; see Supplement). At the end of the treatment, CRP 
correlated weakly with urinary nitrate (r=0.150, P=0.039) and nitrite (r=-0.243, P=0.003) 
excretion, and with UNOxR (r=0.318, P=0.0001).  
 
Postprandial UNOxR changes after ingestion of high-fat protein meals in overweight 
men 
At three different occasions, in a cross-over design, we administered three high-fat meals to 
healthy overweighed men (n=10; BMI > 25 kg/m2; waist circumference >94 cm). The 
meals were made of 1200 kcal from fat (70%) and sucrose (15%) and differed according to 
the nature of the dietary protein, which was either casein (CAS) or whey proteins, enriched 
(LAC) or not (WHE) with α-lactalbumin protein. Morning urine was discarded on the arrival 
at the clinical center; urine was sampled immediately before meal and then collected every 
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2 h for 6 h after the ingestion of the meal. The clinical study has been described in full 
elsewhere (Mariotti et al. 2015). 
When considered all three high-fat meals together, UNOxR did not change upon 
ingestion; UNOxR values also did not change upon ingestion of each meal by the ten 
overweight men (Fig. S2; see Supplement) (Table 1). The baseline UNOxR values varied by 
about 50% on the three meal tests which were performed in a period of at least 6 weeks. 
Considering all data (n=124), urinary creatinine concentration correlated with UNOxR 
(r=0.594, P<0.0001). Creatinine-corrected excretion of nitrite and nitrate correlated with 
each other (r=0.614, P<0.0001) and with UNOxR, yet in an opposite manner: r=-0.591, 
P<0.0001 for nitrite, and r=0.614, P=0.023 for nitrate. 
 
UNOxR in preterm neonates   
In preterm neonates (34 girls, 42 boys) with a gestational age of 23+6 to 36+1 weeks, we 
measured gender-independent UNOxR values of 210±14. The nitrate (283±85 µmol/mmol 
creatinine) and nitrite (4.3±10.7 µmol/mmol creatinine) excretion rates are among the 
highest we measured thus far in healthy adults (Table 1). Creatinine-corrected excretion of 
nitrite and nitrate correlated with each other (r=0.304, P=0.008). Creatinine-corrected 
excretion of nitrite (r=-0.873, P<0.0001), but not of nitrate (r=0.094, P=0.417), did 
correlate with UNOxR. 
 
Effect of L-arginine infusion on UNOxR in growth hormone deficiency   
An indication for a possible effect of L-arginine, which acts on the proximal tubule of the 
nephron, on the reabsorption of urinary nitrite, has provided by the so called L-arginine 
test. We applied this clinical test to seven children suspected to have growth hormone 
deficiency. Infusion of L-arginine (0.5 g L-arginine/kg for 30 min) resulted in peak mM-
concentrations of L-arginine in the plasma and in increases in the creatinine-corrected 
excretion of nitrate (1.1-fold) and nitrite (2-fold); UNOxR decreased by about 40% during the 
test (Schneider et al. 2015) (Table 1). Before starting the L-arginine infusion, creatinine-
corrected nitrate and nitrite correlated with other (r=0.893, P=0.012). UNOxR did correlate 
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inversely with the creatinine-corrected excretion of nitrite (r=-0.893, P=0.012), but not of 
nitrate (r=-0.643, P=0.132). At the end of the L-arginine test, creatinine-corrected 
excretion of nitrate and nitrite correlated with each other (r=0.821, P=0.034), but neither 
nitrate nor nitrite excretion did correlate with UNOxR.    
 
UNOxR in healthy black and white boys  
In urine samples of the age-matched black and white boys from South Africa 
collected in a previously reported study (Mokwatsi et al. 2017), we measured similar nitrite 
and creatinine concentrations but different nitrate concentrations (P=0.0007). These 
differences resulted in statistically significantly (P=0.007) higher UNOxR values in the white 
boys compared to the black boys (mean±SD): 483±314 vs. 314±155 (Table 1). Creatinine-
corrected excretion rates of nitrate and nitrite correlated with each other in the white boys 
(r=0.383, P=0.014) and in the black boys (r=0.501, P=0.001). In the white boys, UNOxR 
correlated more closely with the creatinine-corrected excretion of nitrate (r=0.645, 
P<0.0001) than of nitrite (r=-0.348, P=0.026). In the black boys, UNOxR did not correlate 
with the creatinine-corrected excretion of nitrate (r=0.112, P=0.497), but did correlate 
closely with the creatinine-corrected excretion of nitrite (r=-0.723, P<0.0001). Urinary 
creatinine concentration correlated with UNOxR in the white boys (r=0.570, P=0.0001) and 
in the black boys (r=0.847, P<0.0001). Considering all data (n=80), urinary creatinine 
concentration correlated with UNOxR (r=0.714, P<0.0001). 
 
Animal studies 
UNOxR in the LEW.1AR1-iddm rat as model of human type 1 diabetes mellitus 
To investigate whether the UNOxR can be used as a biomarker for disease state, we 
determined the UNOxR values in urine samples of the LEW.1AR1-iddm rat as a model of 
human T1DM. 
Diabetic and control rats excreted similar amounts of protein in the urine (28±8 vs. 
19±3 µg/mg creatinine). Diabetic rats excreted almost two times higher amounts of nitrate 
than control rats (139±24 vs. 73.8±8.4 µmol/mmol creatinine, P=0.032) (Table 1). This 
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finding agrees with a similar observation in T1DM humans (O´Byrne et al. 2000) and 
suggests enhanced NO synthesis in the diabetic animals. As urinary nitrate does not 
specifically reflect the activity of an individual NOS isoform, the elevated nitrate excretion 
seen in the diabetic rats of the present study and in patients with T1DM (O´Byrne et al. 
2000) may reflect the activity of the inducible (iNOS) as well as eNOS and neuronal NOS 
(nNOS). Urinary nitrite excretion was almost four times higher in the diabetic rats compared 
to the healthy control animals (0.87±0.32 vs. 0.24±0.03 µmol/mmol creatinine, P=0.012). 
The UNOxR was significantly lower in the diabetic rats compared to the control animals 
(198±26 vs. 308±10, P=0.0079, Mann-Whitney test; Fig. 6A). These observations suggest 
that renal reabsorption of nitrite is impaired in the T1DM situation and leads to a higher 
excretion of nitrite. We found a very tight correlation (r=1.00; P=0.02) between urinary 
nitrite and nitrate concentrations in the diabetic rats indicating a coupled nitrite and nitrate 
renal excretion. There was a borderline correlation (r=0.87; P=0.08) between urinary nitrite 
and nitrate in the non-diabetic rats. Diabetic rats excreted statistically insignificantly higher 
amounts of the endogenous NOS inhibitor ADMA than controls (3.96±1.62 vs. 0.70±0.10 
µmol/mmol, P=0.42; Fig. 6B).  
With respect to the urinary excretion of the marker of lipid peroxidation 15(S)-8-iso-
PGF2α, there was no significant difference between diabetic and control rats (21.5±3.93 vs. 
18.4±2.21 nmol/mol creatinine, P=0.84; Fig. 6C), suggesting no elevated oxidative stress in 
the diabetic animals. No correlation was observed between urinary nitrite and 15(S)-8-iso-
PGF2α in the diabetic (r=0.70; P=0.23) and control (r=0.87; P=0.08) rats. Urinary nitrate 
and 15(S)-8-iso-PGF2α also did not correlate in the diabetic (r=0.70; P=0.23) and control 
(r=0.60; P=0.35) rats. There was no correlation between urinary 15(S)-8-iso-PGF2α and 
UNOxR in the diabetic (r=-0.60; P=0.35) and control (r=-0.90; P=0.08) rats. UNOxR did not 
correlate with urinary ADMA in the diabetic or in the non-diabetic rats (data not shown). 
In summary, renal CA-dependent nitrite reabsorption is decreased in the human 
T1DM LEW.1AR1-iddm rat model, presumably by mechanisms independent of oxidative 
stress. 
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UNOxR in dyslipidemic APOE*3-Leiden.CETP mice 
The APOE*3-Leiden.CETP mice are a unique model for human-like lipoprotein metabolism, 
which shows a similar response to lipid-lowering drugs including statins as in humans both 
with respect to changes in magnitude and dosage of the drugs. In dyslipidemic APOE*3-
Leiden.CETP mice treated with resveratrol and/or atorvastatin, only a combination of 
resveratrol and atorvastatin was found to increase slightly UNOxR (Fig. 7A), with no changes 
in the urinary concentrations of 15(S)-8-iso-PGF2 (Berbée et al. 2013). Thus, the 
combination of resveratrol and atorvastatin is likely to improve the CA-dependent 
reabsorption of nitrite. 
Of the antiretroviral protease inhibitor drugs tested, only ritonavir at 60 mg/kg 
bodyweight per day increased the UNOxR values in APOE*3-Leiden.CETP mice as compared 
to placebo (mean±SEM) from 194±52 to 463±60 (P=0.0056); a lower dose of ritonavir (10 
mg/kg bodyweight per day) in combination with lopinavir had no effect (Fig. 7B). These 
findings suggest that ritonavir and/or its metabolites may impair renal CA-dependent nitrite 
reabsorption. Our results are in line with data from the literature that point to an inhibition 
of CA activity by ritonavir (Denissen et al. 1997; Supuran 2008; Haque et al. 2012).   
 
Stable-isotope dilution techniques – the U15NOxR  
In studies on renal CA-dependent nitrite reabsorption (Tsikas et al. 2010b; Chobanyan-
Jürgens et al. 2012a) and CA-dependent formation of S-nitrosothiols (Zinke et al. 2015), 
the use of stable-isotope labelled nitrate and nitrite, notably [15N]nitrate and [15N]nitrite, is 
safe, provides valuable information and is therefore highly recommended in experimental 
and clinical studies. Urinary [15N]nitrate and [15N]nitrite may derive from ingested authentic 
inorganic [15N]nitrite salts (Fig. 8A; Fig. S3). [15N]Nitrate and [15N]nitrite may also derive 
from [15N]NO produced from ingested L-[guanidine-15N2]-arginine by NOS (Kayacelebi et al. 
2015) (Fig. 8B). Finally, [15N]nitrate and [15N]nitrite may also derive from organic nitrates 
(Fig. 1) labelled with 15N in their nitrate groups, such as [15N]PETN, [15N]ISDN or [15N]GTN 
(glycerol trinitrate). Simultaneous measurement of [15N]nitrate and [15N]nitrite in blood and 
urine samples from such studies by GC-MS (Tsikas et al. 2010b), and calculation of the 
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U15NOxR value generated significant information about renal CA-dependent nitrite 
reabsorption. U15NOxR is simply calculated by dividing the peak area ratio (PAR) of the mass-
to-charge (m/z) ratio of 63 (15NO3–) to 62 (14NO3–) to the PAR of m/z of 47 (15NO2–) to 46 
(14NO2–) which corresponds to the ratio of the molar ratios [15N]nitrate/[14N]nitrate and 
[15N]nitrite/[14N]nitrite (Fig. S3). Thus, U15NOxR is not entirely comparable with UNOxR. Due 
to the natural abundance of 0.36% of the isotope 15N of the element N, the molar ratio of 
[15N]nitrate/[14N]nitrate is almost equal with the molar ratio of [15N]nitrite/[14N]nitrite. It 
results from this that the value of U15NOxR is practically equal to 1 in urine samples at 
baseline, that means, prior to ingestion of [15N]nitrate, [15N]nitrite or 15N-labelled 
compounds such as L-[guanidine-15N2]-arginine that may serve as a source for [15N]nitrate 
and/or [15N]nitrite.  
 Upon ingestion of 15N-labelled species such as the sodium salt of [15N]nitrite, U15NOxR 
may reach values above or below of 1. Fig. 8A shows that drinking of sodium[15N]nitrite 
diluted in water by a healthy subject resulted in a gradual increase of the U15NOxR value 
indicating a lower excretion rate of [15N]nitrite in the urine compared to [15N]nitrate which is 
produced from ingested [15N]nitrite (see also Fig. S3). However, when [15N]nitrite is 
ingested a few minutes after the ingestion of acetazolamide, the U15NOxR value decreases 
suddenly to reach values below 1. This indicates that the excretion of [15N]nitrite into the 
urine increased drastically compared to the urinary excretion of [15N]nitrate. [15N]Nitrate is 
rapidly formed from [15N]nitrite oxidation in erythrocytes by oxyhemoglobin. Subsequently, 
the U15NOxR value reaches its baseline value already 2 h after the second ingestion of 
sodium [15N]nitrite. 
 In the two mice which drank for four days L-[guanidine-15N2]-arginine diluted in tap 
water, the U15NOxR value increased from the baseline value of 1 to a plateau of a value 
around 2 after two days (Fig. 8B). This finding suggests that ingested L-[guanidine-15N2]-
arginine was absorbed and partly oxidized to 15NO. Subsequently, 15NO was oxidized to 
[15N]nitrate and [15N]nitrite which were then excreted in the urine. Obviously, it takes about 
two days until a steady state is reached between L-[guanidine-15N2]-arginine absorption, 
NOS-catalyzed conversion to 15NO and renal excretion of its metabolites [15N]nitrate and 
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[15N]nitrite. The increase of the U15NOxR value from 1 to 2 suggests that the molar ratio of 
[15N]nitrate and [15N]nitrite formed from 15NO produced by NOS from synthetic L-
[guanidine-15N2]-arginine differs from the molar ratio of [15N]nitrate and [15N]nitrite 
obtained from 15NO produced by NOS from endogenous L-[guanidine-15N2]-arginine, and 
from other sources (see Fig. 1). 
 
 
Discussion 
One of the major tasks of the renal proximal tubule is to secrete protons into the tubule 
lumen, thereby reabsorbing about 80% of the filtered bicarbonate (for review see Boron 
2006). CAII and CAIV, sodium-proton exchanger 3 (NHE3), several aquaporins (AQP) and 
anion exchangers (AE) are parts of the renal proximal tubule arsenal that regulates the 
acid-base transport (Boron 2006). In humans, we found that renal CA isoforms are involved 
in the reabsorption of inorganic nitrite (NO2–) and to a lesser extent of inorganic nitrate 
(ONO2–) (Tsikas and Chobanyan-Jürgens 2010; Tsikas et al. 2010; Chobanyan-Jürgens et 
al. 2012a). Purified bovine erythrocytic CAII has been reported to generate NO from nitrite 
in the presence of the CA inhibitor dorzolamide (Aamand et al. 2009). The underlying 
mechanisms of these potentially novel functions of the CA family are not yet known. Recent 
findings from our group indicate that bovine and recombinant human CAII and CAIV acidify 
NO2– to nitrous acid (HONO) which is chemically reactive and undergoes further reactions 
(Zinke et al. 2015) (Fig. 1). They include S-nitrosylation of cysteinyl thiols (RCysSH) which 
leads to formation of S-nitrosothiols such as GSNO and CysSNO (Hanff et al. 2015). S-
Nitrosothiols exert NO-related bioactivity via cGMP-dependent and cGMP-independent 
mechanisms (Tsikas et al. 1999). Furthermore, phosphorylation of CA, another 
posttranslational modification, has been shown to modulate its intrinsic carbonic anhydrase 
activity (Carrie and Gilmour 2015).  
 Nitrite may directly derive from NO (via autoxidation) or from nitrate (including 
nitrate produced from NO and nitrite oxidized by oxyhemoglobin in erythrocytes) by the 
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action of nitrate reductases in the mouth and gut flora (Fig. 1). In vitro, we found that 
nitrite can react chemically with CO2 to form most likely nitritocarbonate (O=N-O-COO2–) 
and that this reaction can be modulated by bovine erythrocytic CAII (Chobanyan-Jürgens et 
al. 2012; Tsikas et al. 2016). Inorganic nitrite and nitrate are mainly eliminated by the 
kidneys. In healthy adults, the creatinine-corrected excretion rates of nitrite and nitrate are 
in the range 0.08 – 0.30 µmol/mmol creatinine and 90 – 110 µmol/mmol creatinine, 
respectively, i.e., the nitrate excretion is more than two orders of magnitude higher than 
that of nitrite (Tsikas 2008). In humans, oral intake of the CA inhibitor acetazolamide 
resulted in highly enhanced excretion of endogenous nitrite and of orally administered 
[15N]nitrite (Tsikas and Chobanyan-Jürgens 2010; Tsikas et al. 2010; Chobanyan-Jürgens et 
al. 2012a), suggesting that the reabsorption of nitrite from the primary urine is mediated, 
at least in part, by renal CA isoforms. The molar ratio of urinary nitrate to urinary nitrite, 
i.e., UNOxR, describes the urinary excretion of nitrite relative to nitrate (Fig. 1). Thus, we 
hypothesized that UNOxR may be a useful measure of renal CA-dependent reabsorption of 
urinary nitrite in humans. UNOxR considers the ONO2–/NO2–/NO cycle (Weitzberg and 
Lundberg 2013) and may therefore provide important quantitative information about the 
size of the NO reservoir/bioavailability in the circulation (Fig. 1). We assumed that higher 
UNOxR values would indicate a more abundant ONO2–/NO2–/NO cycle and thus a healthier 
organism than lower UNOxR values. We were therefore interested in learning more about this 
potentially useful biomarker in different conditions. In this work, we present novel results 
and undertake a first evaluation of the utility of UNOxR as a measure of renal CA-dependent 
reabsorption of nitrite in experimental and human studies by performing a meta-analysis of 
results previously reported by our and other groups (Table 1). 
 
Autoimmune and inflammatory diseases 
In healthy adults, average UNOxR reaches values ranging between about 400 and 1600 
(Table 1). Autoimmunity and inflammation characterize rheumatic diseases, T1DM and to a 
lesser extent also T2DM. The several times lower UNOxR values we measured in adult 
patients suffering from T2DM or chronic rheumatic diseases, including rheumatoid arthritis, 
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spondyloarthritis and vasculitis (Table 1), are indicative of an impaired renal CA-dependent 
reabsorption of nitrite (Fig. 1). The finding that the UNOxR was independent of age, disease 
duration and markers of inflammation in the T2DM patients of the DALI study suggests that 
impairment of this kind of CA activity may manifest itself early in the disease and may not 
further exacerbate in elderly patients with age, disease duration and inflammation degree. 
Compared to healthy elderly subjects, elderly patients with PAOD or CAD had similar UNOxR 
values (Table 1), which were moreover comparable with those measured in ten obese but 
otherwise healthy men (Table 1). 
The finding that T1DM rats have lower UNOxR values than healthy non-diabetic rats 
greatly supports the idea that T1DM rats suffer from impaired renal CA-mediated 
reabsorption of urinary nitrite. Because our rat model shares major characteristics with 
human T1DM (Jörns et al. 2014), T1DM patients may also suffer from diminished NO 
bioactivity as a result of impaired renal CA-dependent reabsorption of nitrite. This is of 
particular importance because nitrite in the circulation and in tissues is considered a major 
NO reservoir (Gladwin et al. 2006) (Fig. 1). 
As cardiovascular complications are rare in early stage T1DM patients, we 
hypothesise that the renal reabsorption of nitrite is intact or only weakly impaired in T1DM. 
Unfortunately, we have no data about UNOxR in adults suffering from T1DM. It should be 
pointed out that the L-Arg/NO pathway differs greatly in childhood and adulthood, with 
differences also including circulating and excretory nitrate and nitrite (Lücke et al. 2007). 
Therefore, UNOxR values measured in childhood and adulthood are not easy to compare. It is 
worth mentioning that in 102 T1DM children the UNOxR values (mean±SD) of 1192±592 are 
even higher than those measured in healthy non-diabetic children (Carmann et al. 2015) 
(Table 1). However, in children suffering from Duchenne muscular dystrophy (DMD), the 
UNOxR values were significantly lower compared to healthy children and those with T1DM 
(Table 1). Interestingly, newly diagnosed untreated T1DM children and medicated T1DM 
children were found to have comparable UNOxR values. However, insulin-treatment has 
halved the urinary excretion of both, nitrite and nitrate, to a comparable degree.   
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 Atorvastatin administration at 10 mg/d or 80 mg/d for 30 weeks was found not to 
alter synthesis of NO, prostacyclin or thromboxane, and not to decrease oxidative stress in 
the adult T2DM patients of the DALI study (Tsikas et al. 2015). These observations are in 
line with the absence of an appreciable change in UNOxR upon atorvastatin treatment both in 
the DALI study and in the APOE*3-Leiden.CETP mice. In this model, only a combination of 
resveratrol and atorvastatin slightly increased UNOxR, with no changes in the urinary 
concentrations of nitrite, nitrate and 15(S)-8-iso-PGF2 (Tsikas et al. 2015), a widely used 
biomarker of oxidative stress (Tsikas 2017). In T2DM, the correlation between UNOxR with 
CRP became significant after 30 weeks of atorvastatin administration UNOxR (r=0.318, 
P=0.0001). This may be due to the atorvastatin-mediated reduction of the CRP levels in the 
DALI study (van der Ree et al. 2003). 
In the APOE*3-Leiden.CETP mice, of the orally administered HIV-1 protease 
inhibitors tested, i.e., ritonavir, lopinavir and atazanavir, only ritonavir lowered UNOxR. This 
observation suggests that ritonavir itself and/or its metabolites might have inhibited CA-
mediated reabsorption of nitrite in the kidneys of the animals, thus leading to a higher loss 
of NO bioavailability in the form of elevated urinary excretion of nitrite. The finding that the 
lopinavir/ritonavir combination did not lower significantly the UNOxR value is likely to be due 
to a lacking effect of lopinavir on renal CA-mediated reabsorption of nitrite in combination 
with a smaller ritonavir effect because of its lower dose used in the combination with 
lopinavir compared with ritonavir alone (10 mg/kg/d vs. 60 mg/kg/d). This finding is 
supported by observations indicating that many drugs, including protease inhibitors such as 
ritonavir, cause proximal renal tubular acidosis, most likely by interacting with renal CA 
isoforms in the proximal tubule (Liu et al. 2012). An explanation for the inhibitory effect of 
ritonavir and the lacking effects of lopinavir and atazanavir on nitrite reabsorption by renal 
CA isoforms is likely to be due to the thiazole moiety of ritonavir, which is absent in 
lopinavir and atazanavir. In humans, ritonavir is metabolized to numerous more polar 
metabolites of which many contain the non-substituted thiazole moiety (Denissen et al. 
1997). Three of the identified ritonavir metabolites are formed by decarbamoylation of 
ritonavir. The thiazolyl moiety released by this biotransformation is expected to be 
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chemically unstable and is likely to lose CO2 thereby forming 4-(hydroxymethyl)-1,3-thiazol. 
The latter is structurally related to the CA inhibitor acetazolamide and other biologically 
active drugs, and is bearing furthermore a chemically reactive thiocyanate group like the 
experimental CA inhibitor DIDS (Tsikas et al. 2013).  
 
Ethnic differences with regard to UNOxR  
Hypertension is a particularly common finding in black populations. Hypertension occurs at 
younger ages and results in a higher incidence of cardiovascular disease and mortality in 
blacks, yet the reasons are incompletely understood (Schutte et al. 2017). The lower UNOxR 
values found in the black boys of the present study (Table 1) could be an indication of a 
lower reabsorption rate of nitrite compared to the white boys, presumably due to genetic 
differences in renal CA isoforms and anion transporters.  
 
UNOxR as an indicator and measure of tolerance development to organic nitrates?  
An interesting finding of our study is that at therapeutically relevant and equivalent oral 
dosages, the organic nitrates PETN and ISDN caused a decrease in the UNOxR values already 
one day after starting drug administration, whereas the decrease was more pronounced for 
ISDN. By definition, high UNOxR values indicate efficient CA-dependent reabsorption of 
urinary nitrite, while low UNOxR values indicate impaired CA-dependent nitrite reabsorption 
thus resulting loss of NO bioactivity (Fig. 1). Based on these assumptions, our findings 
concerning the urinary excretion of nitrite and nitrate upon oral intake of the organic 
nitrates by healthy young adults would indicate that intake of ISDN causes a stronger loss 
of NO bioactivity compared to PETN. Such an interpretation would be in line with the 
currently prevailing and increasingly supported idea that ISDN but not PETN induces 
tolerance and endothelial dysfunction (Thum et al. 2011; Münzel et al. 2014). Previously, 
we demonstrated that in healthy young men and at therapeutically relevant doses neither 
ISDN nor PETN induce oxidative stress (Keimer et al. 2003), which is considered a major 
factor in endothelial dysfunction because it decreases NO bioavailability through NO 
oxidation to nitrite, nitrate and peroxynitrite. It is interesting to note that chronic oral 
 
 
 
29 
 
ingestion of inorganic nitrate, i.e., drinking of a NaNO3 solution in tap water, did not alter 
the UNOxR values in young healthy men (Hanff et al. 2017). Men (n=9) who ingested NaNO3 
(0.1 mmol/kg/d) had even higher UNOxR values than men (n=8) who ingested placebo 
(NaCl, 0.1 mmol/kg/d): 1709±355 vs. 369±77, without concomitant changes in plasma 
creatinine concentration (Hanff et al. 2017). The incompletely understood mechanisms 
underlying the still enigmatic phenomenon of tolerance development to organic nitrates 
(Mayer and Beretta 2008) and the potential role of renal CA isoforms remain to be further 
investigated, and UNOxR could be a useful parameter in forthcoming studies. 
 
 
Mechanistic considerations 
The mechanisms by which nitrite and nitrate are excreted into and reabsorbed from the 
primary urine in humans are incompletely understood. Our studies, especially those 
involving the use of acetazolamide, a strong clinically used CA inhibitor, indicate that one 
important mechanism is likely to be based on renal CA isoforms (Fig. 1). In addition to renal 
CA, anion transport systems may also regulate the excretion and the reabsorption of the 
anions nitrite and nitrate in the kidney, presumably in parallel with the CA-dependent 
bicarbonate transport. It is noteworthy that inorganic nitrite (NO2–), but not inorganic 
nitrate (NO3–), reacts chemically with CO2, i.e., the substrate of CA isoforms including CAIV 
(Tsikas et al. 2013, 2016). This specific reaction could make nitrite reabsorption in the 
nephron even more accessible to variations in CA activity and expression in the kidneys. 
The underlying mechanism of the elevated nitrite excretion in diabetes and chronic 
rheumatic diseases in adults is likely to involve impaired reabsorption of nitrite in the 
proximal tubule as the result of altered activity and/or expression of the membrane-bound 
CAIV and the cytosolic CAII in the nephron. Literature reports (Liu et al. 2012; Gambhir et 
al. 2007) are supportive of the involvement of renal (and erythrocytic) CA isoforms in 
diabetes and other autoimmune diseases.  
  A considerable fraction of circulating nitrite and nitrate originates from sources other 
than the L-Arg/NO pathway (Fig. 1). A major contributor is nutrition (Weitzberg and 
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Lundberg 2013). Our studies indicate that the UNOxR may vary considerably (by 50 to 60%) 
in healthy non-medicated humans. One important factor for the UNOxR variability seems to 
be the pH value of the urine, which physiologically varies between about 4.5 and 8.5 over 
the day in healthy humans (Bilobrov et al. 1990; Murayama et al. 2001). Inhibition of renal 
CA activity by drugs such as acetazolamide will acutely and strongly decrease the UNOxR 
over several hours. Other widely used drugs such as NAC (Tsikas et al. 2014) and 
paracetamol (Trettin et al. 2014) are weak CA inhibitors and are not expected to decrease 
strongly the UNOxR value when used at therapeutically relevant doses. Yet, individuals may 
respond differently to these and possibly to other drugs. 
In male white mice (18-20 g bodyweight), intraperitoneal injection of NaHCO3 (2000 
mg/kg) was found to reduce methemoglobinemia previously induced by intraperitoneal 
injection of NaNO2 (150 mg/kg) and to prolong the survival time by improving vital 
biochemical pathways including the antioxidative defense system in erythrocytes (Shugaleĭ 
et al. 1994). This group assumed that the protective effect of administered bicarbonate was 
due to its reaction with hydrogen peroxide, superoxide and hydroxyl radicals (Shugaleĭ et 
al. 1994). Although such reactions cannot be excluded, we think that the main effects were 
due to greatly enhanced renal elimination of nitrite rather than of NaNO2-derived nitrate. 
Obviously, alkalization of the urine by pharmacological bicarbonate resembles the effect of 
the clinical CA inhibitor acetazolamide on nitrite reabsorption (see Fig. 2). Unfortunately, 
measurements of nitrite, nitrate, bicarbonate and pH in blood and urine samples of the mice 
intoxicated by NaNO2 had not been reported (Shugaleĭ et al. 1994).   
 Recent studies indicate that certain CA isoforms are responsible for the chemical 
activation of nitrite to strongly nitrosating NO-species (Aamand et al. 2009; Zinke et al. 
2016; Hanff et al. 2016). Protons provided by CA at neutral pH are likely to protonate nitrite 
to nitrous acid (HONO, pKa 3.4) which may also form its anhydride (N2O3) (Fig. 1). HONO 
and N2O3 are potent nitrosating species. Thus, bovine and human CAII and CIV were found 
to nitrosate thiols on their sulfur atom (S-nitrosylation) and tyrosine on one of its aromatic 
C atoms (C-nitrosylation) (Zinke et al. 2016, Hanff et al. 2016). Physiological S-nitrosothiols 
such as S-nitrosohemoglobin (HbCysSNO), GSNO and CysSNO can exert biological activity 
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by mechanisms depending on cGMP or independent of cGMP (Tsikas et al. 1999). Well-
known biological activity exerted by HbCysSNO, GSNO and CysSNO includes vasodilation 
and inhibition of platelet aggregation (Tsikas 2008) (Fig. 1). Because of the lacking 
specificity of HONO and N2O3 towards substrates, these species may also nitrosate amines 
on their amine groups. It is therefore reasonable to assume that CA may also catalyze the 
N-nitrosylation of particular amines and amino acids (Fig. 1). As an example, sarcosine (N-
methylglycine) is subject to N-nitrosation to form N-nitrososarcosine. This nitrosamine is 
chemically highly reactive and a potent alkylating species towards biomolecules such as 
guanine, and as such has a mutagenic and cancerogenic potential (de Vogel et al. 2014; 
Krishnamurthy et al. 2006, 2013). Thus, CA is a versatile enzyme family which possesses 
many additional activities and functions beyond its inherent carbonic anhydrase activity and 
pH regulation in various biological systems.  
 
Possible limitations for the clinical use of UNOxR as a measure of renal CA-
dependent reabsorption of nitrite 
Very low UNOxR values may arise from high (lower µM-range) urinary nitrite concentrations 
due to bacteriuria (Chao et al. 2016) and/or improper collection and storage conditions of 
urine samples. It is noteworthy that in urine nitrate exists in a very high molar excess over 
nitrite, so that reduction of even a very small fraction of nitrate to nitrite by bacterial nitrate 
reductases may considerably decrease the UNOxR value. In the studies reported in the 
present work such unfavourable conditions were avoided. The highest urinary nitrite 
concentrations and the lowest UNOxR values were measured in the T2DM patients of the 
DALI study. The prevalence of (asymptomatic) bacteriuria in T1DM and T2DM inpatients and 
outpatients is about two times higher than in non-diabetic persons and may reach values 
ranging between 2 and 14% of the whole cohort (Keane et al. 1988; Ishay et al. 2006; 
Matteucci et al. 2007; Renko et al. 2011). Complete avoidance of bacteriuria in subjects 
participating in clinical studies is therefore almost impossible. Nevertheless, bacteriuria 
must not always be associated with enhanced bacterial reduction of nitrate to nitrite. 
Bacterial colonization in the urinary tract may also induce iNOS expression in macrophages, 
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thus contributing large amounts of L-Arg/NO-derived nitrite independent of bacterial nitrate 
reductase activity. Recently, we discovered that CA isoforms are also expressed in human 
penile erectile tissue (Ückert et al. 2016). This may be of particular importance because 
many CA isoforms are associated with cancer (Takakura et al. 2012). For many decades 
inorganic nitrite from certain foods is considered as a key nitrosating species (Lewin et al. 
2006). It remains to be investigated whether certain CA isoforms are also involved in the 
bioactivation of nitrite to form alkylating N-nitrosamines, i.e., beyond NO and RSNO 
formation (N-Nitrosamines (15 listings): N-Nitrososarcosine 2011). Sarcosine (N-
methylglycine) is considered as a biomarker for prostate cancer (Sreekumar et al. 2009; 
Cheng et al. 2010; Cernei et al. 2013) (Fig. 1).  
 Several bacteria are known to express CA, and inhibition of bacterial CA can lead to 
debilitation and changes in the metabolism of the microorganisms (Capasso and Supuran 
2017), presumably including the nitrate-to-nitrite conversion rate. For this and other 
reasons (Sütö et al. 1995; present study), UNOxR in experimental and clinical studies 
involving use of CA inhibitors is likely to be compromised.   
 In some of our human studies, urine from spontaneous micturition was freshly 
collected and immediately analyzed or was frozen aliquoted at -20 °C. In other human 
studies, in which urine had to be collected over the day (e.g., Keimer et al. 2003; Tsikas 
and Kinzel 2017), we took precautions to avoid both, loss of nitrite which takes place under 
acidic conditions and artefactual formation due to bacterial nitrate reductase activity. Use of 
control groups, standard operation procedures for nutrition (i.e., low nitrate/nitrite diet), 
medication (e.g., organic nitrates), overnight fasting, as well as for urine sampling and 
storage and use of preservatives, such as a combination of EDTA and 4-hydroxy-TEMPO or 
organic solvents, and use of highly specific methods for the accurate measurement of nitrite 
in the presence of huge amounts of nitrate are required for the reliable assessment of UNOxR 
in experimental and clinical studies. These issues are of particular importance in studies 
involving children, where urine collection often represents a pragmatic challenge. 
 Being small anions, both nitrate and nitrite can be transported by several different 
cellular mechanisms. Most of the reported studies have used nitrate and nitrite at very high 
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mM-concentrations. In pancreatic acinar cells, the transport of nitrite was found to be 
coupled to CO2-bicarbonate transporters and to be affected by CA leading to cytosolic 
acidification (e.g., by 0.034 pH-units at 0.1 mM nitrite; Zhao et al. 1994). This group 
considered nitrous acid (HONO) and other higher nitrogen oxides as the acidifying species in 
a manner depending on CA. In a variety of mammalian cells, nitrate (used at mM 
concentrations) has been reported to be transported by NO3‒-H+ cotransporters which were 
only marginally dependent upon CA (Chow et al. 1997). Anion exchangers (AE) including 
AE1, AE2, and AE3, the main chloride-bicarbonate co-transporters, have been shown to be 
coupled to CAII thus building a bicarbonate transport metabolon (Sterling et al. 2001). This 
interaction seems to be required for maximum bicarbonate transport. Eventually, 
aquaporin-6 (AQP-6) has been reported to serve as a channel for nitrate in mammalian cells 
(Ikeda et al. 2002). Obviously, nitrate and nitrite are transported by several different 
mechanisms which are in part coupled to the bicarbonate transport and thus to CA activity. 
The quantitative contribution of the individual transport mechanisms is currently unknown 
and remains to be determined in sophisticated studies. Our studies suggest that in humans 
the renal CAII and CAIV have considerable selectivity towards nitrite (Tsikas and 
Chobanyan-Jürgens 2010; Chobanyan-Jürgens et al. 2012a; Tsikas et al. 2014). In the far 
majority of our studies, urinary nitrate and nitrite correlated directly with each other 
(correlation coefficient range, 0.335 – 0.893). Without exception, creatinine-corrected 
excretion of nitrite correlated inversely with UNOxR (correlation coefficient range, 0.348 – 
0.893), while the correlation of UNOxR with the creatinine-corrected excretion of nitrate was 
not uniform, albeit mostly positive. These studies suggest that the urinary nitrite excretion 
is a much stronger predominant term of UNOxR than urinary nitrate excretion. UNOxR may 
therefore be useful as a measure of renal CA-dependent nitrite reabsorption in health and 
disease. The reabsorption capacity of renal CA and other transport systems towards urinary 
nitrite is unknown. The results of our clinical study with PETN and ISDN suggest that the 
renal reabsorption capacity is limited. Daily intake of 240 mg (0.76 mmol) PETN or 90 mg 
(0.38 mmol) ISDN can considerably decrease the UNOxR value. Considering stoichiometric 
and quantitative conversion of the nitrate groups of PETN and ISDN to NO, it seems that 
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daily formation of 3.04 mmol NO from PETN and of 0.76 mmol NO from ISDN can decrease 
remarkably the UNOxR and thus the renal reabsorption capacity for nitrite. It remains to be 
demonstrated whether partly and/or entirely denitrated metabolites of PETN and ISDN are 
involved in the reduction of UNOxR, while chronic ingestion of high amounts of inorganic 
nitrate does not decrease UNOxR.  On the other hand, inhibition of renal CA by acetazolamide 
seems to force the diuresis of nitrite for several hours in parallel to bicarbonate.   
 
Summary 
There is increasing evidence that the excretion of nitrite in the urine is coupled, at least in 
part, to the CA activity in the proximal tubule of the nephron. The molar ratio of urinary 
nitrate to urinary nitrite, i.e., the measure UNOxR, may be a suitable measure of the CA-
dependent reabsorption of nitrite in adults and children (Table 1, Fig. S4). Thus, UNOxR may 
be a useful measure of the NO bioavailability in the renal and cardiovascular systems in 
health, disease and pharmacotherapy. In PAOD patients, UNOxR is inversely correlated with 
blood pressure and suggests that elevated excretion or diminished reabsorption of nitrite 
may decisively determine NO-dependent biological activity, namely vasodilation. Of 
particular importance could be the use of UNOxR in identifying and quantitating tolerance to 
established and novel organic nitrates, to other so-called NO donors and to the currently 
increasingly used inorganic nitrate and nitrite in experimental and clinical studies. Accurate 
determination of UNOxR, which seems to vary considerably in humans, requires use of proper 
pre-analytical precautions, notably avoidance/minimization of bacterial infection, and most 
importantly use of specific and sensitive analytical methods for urinary nitrite (upper nM- to 
lower µM-range) in the presence of high molar excess of nitrate (upper µM- to lower mM-
range). The simultaneous GC-MS measurement of nitrite and nitrate in urine samples as 
pentafluorobenzyl derivatives (Tsikas 2000) is best suited for the study of nitrite-related CA 
activity in the urogenital, renal and cardiovascular systems. Of particular importance is the 
CA-dependent reabsorption of nitrite in the kidney and the bioactivation of nitrite to S-
nitrosothiols, NO, nitrosoamines and nitrotyrosine in various types of cell including 
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erythrocytes and muscle cells. Acetazolamide may decrease systolic blood pressure and 
increase cardiac output, thereby increasing cerebral blood flow (Hauge et al. 1983). 
Acetazolamide can enhance nitrite-induced radial artery dilation (Omar et al. 2015). It can 
thus be expected that CA isoforms may exert different nitrite-related effects in the brain, in 
the cardiovascular and renal systems. 
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Figure legends 
 
Fig. 1. Sources of nitric oxide (NO), nitrite and nitrate and simplified proposed mechanisms 
for the bioactivation of inorganic nitrite. For more details see the text. Abbreviations: CA, 
Carbonic anhydrase; CysSH, L-cysteine; CysSNO, S-nitroso-L.cysteine; GSNO, S-nitroso 
glutathione; Hb, hemoglobin; HbFeNO, nitrosyl hemoglobin; HbCysSNO, S-nitroso 
hemoglobin; NxOy, higher nitrogen oxides; UNOxR, urinary nitrate-to-nitrite molar ratio; XOR, 
xanthine oxidoreductase. Symbols: (+), activation; (-), inhibition.   
 
Fig. 2. Mean urinary concentrations of nitrate, nitrite and bicarbonate (A), mean creatinine-
corrected urinary excretion of nitrate (B) and nitrite (C), and mean UNOxR (D) in urine 
samples collected by seven healthy subjects before and after oral intake of the CA inhibitor 
acetazolamide (a 500-mg Diamox retard capsule, corresponding to 5 mg/kg body weight). 
This Figure was constructed by using the data reported in previous study (Tsikas and 
Chobanyan-Jürgens 2010) and the newly measuring nitrite and nitrate concentrations in the 
urine samples (see Fig. 5B in Tsikas and Chobanyan-Jürgens 2010). The vertical dotted line 
in (A) separates regimes with existing and missing correlations between the parameters.   
 
Fig. 3. (A) UNOxR in 18 healthy previously non-medicated young men at baseline on day 1 
and day 21. (B) Decadic logarithm of UNOxR in 18 healthy previously non-medicated young 
(DAY 0), after 1 day (DAY 1), and after 5 (DAY 5) days of oral intake of PETN or ISDN. This 
Figure was constructed by using the individual urinary nitrate and nitrite concentrations 
reported elsewhere (Keimer et al. 2003).  
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Fig. 4. Relationship between systolic or diastolic pressure and UNOxR in 37 elderly patients 
suffering from peripheral artery occlusive disease (PAOD). The anthropometric and clinical 
characteristics of the PAOD patients have been reported in previous study (Schneider et al. 
2015). The Figure was prepared using the baseline data of this study. 
 
Fig. 5. UNOxR in healthy non-medicated men (n=25) and women (n=16) (A), and 
relationship between UNOxR and urinary pH (B) or age (C) in the whole group. This Figure 
was constructed by using the individual nitrate and nitrite concentrations reported 
elsewhere (Pham et al. 2009).  
 
Fig. 6. UNOxR (A), ADMA (B) and 15(S)-8-iso-PGF2α (C) in healthy non-diabetic rats (n=5) 
and in T1DM rats (n=5). Data are presented as mean± SEM. 
 
Fig. 7. (A) UNOxR in untreated (Control) and APOE*3-Leiden.CETP mice fed with resveratrol 
(Res), atorvastatin (Ator), or with resveratrol plus atorvastatin (Res+Ator). This Figure was 
constructed using newly determined urinary nitrate and nitrite concentrations of a 
previously reported study (Berbeée et al. 2013). (B) UNOxR in untreated (Placebo) and 
APOE*3-Leiden.CETP mice treated with ritonavir, lopinavir+ritonavir or atazanavir (n=9 per 
group). Data are presented as mean±SEM. 
 
Fig. 8. (A) Urinary [15N]nitrate-to-[15N]nitrite molar ratio U15NOxR in a healthy female 
volunteer (age, 25 years) who drank two times [15N]nitrite sodium dissolved in drinking 
water (0.31 µmol/kg each) and took once acetazolamide (5.4 mg/kg bodyweight) at the 
time points indicated by arrows. The first [15N]nitrite occurred at the time point “0”. This 
Figure was constructed using data of a previously reported study (Tsikas et al. 2010b). Note 
that the U15NOxR value is calculated by dividing the ratio [15N]nitrate/[14N]nitrate by the ratio 
[15N]nitrite/[14N]nitrite. GC-MS chromatograms from urine analyses collected before and 
after [15N]nitrite sodium intake are shown in the Supplement (Fig. S3). (B) U15NOxR in two 
mice which drank L-[guanidine-15N2]-arginine-containing drinking water (100 µg/mL, 568 
µM) for four days. [15N]nitrate, [15N]nitrite, [14N]nitrate and [14N]nitrite were measured 
simultaneously by GC-MS (Tsikas 2000). This Figure was constructed using data of a 
previously reported study (Tsikas 2004). Note that the U15NOxR value is calculated by 
dividing the ratio [15N]nitrate/[14N]nitrate by the ratio [15N]nitrite/[14N]nitrite. Due to the 
natural abundance of 0.36% of the isotope 15N of the element N, the ratios 
[15N]nitrate/[14N]nitrate and [15N]nitrite/[14N]nitrite are practically equal and the U15NOxR 
value is close to 1 in urine samples collected prior to drink synthetic L-[guanidine-15N2]-
arginine-containing tap water.  
 
Table 1 Summary of baseline urinary nitrate, nitrite and UNOxR values reported in the literature and in the present work for healthy and 
diseased humans, rats and mice, and calculated from reported urinary excretion rates of nitrate and nitrite 
____________________________________________________________________________________________________________________________________________ 
Health state   Age   [NO3–]   [NO2–]    UNOxR   Reference 
    (years)     (µmol/mmol creatinine) (µmol/mmol creatinine)  (—)    
________________________________________________________________________________________________________________________________________________________________ 
Adults a 
Healthy men (n=18)  26.4 ± 2.7  97.6 ± 13.2  0.075 ± 0.009   1570 ± 233  Keimer et al. (2003) 
Healthy men (n=15)  24.2 ± 2.5  90.5 ± 15.6  0.29 ± 0.06   406 ± 61   Fahlbusch et al. (2004) 
Healthy (16 f/25 m)  47 [26 – 82]  106 ± 12   0.19 ± 0.02   660 ± 72   Pham et al. (2009) 
Hypogonadal men (n=8)  49 ± 8.9   74 [54-91]  0.56 [0.37-0.79]   123 ± 33   Tsikas & Kinzel (2017) 
Rheumatic (18 f/10 m)  55 [23 – 82]  105 ± 13   1.10 ± 0.30   187 ± 22   Pham et al. (2009) 
Transplantation (2 f/7 m)  45.7 ± 14.7  89 ± 80   0.55 ± 0.92   689 [100-1056] b  Becker et al. (2009) 
       125 ± 148  1.43 ± 1.00   55.6 [34-133] c 
       147 ± 123  2.76 ± 2.13   38.4 [24-125] d 
CAD (12 f/48 m)   62   87.0 [80-125] (PLA) 0.19 [0.13-0.58] (PLA)  408 [236-736] (n=168) Schneider et al. (2015) 
       78.0 [72-117] (ARG) 0.20 [0.16-0.57] (PLA)   
PAOD (9 f/31 m)   68 ± 8   68.1 [55-105]  0.18 [0.11-0.30]   400 [295-579]  Schneider et al. (2015) 
Obese (n=10 m; BMI>25)  21 – 50   76.8 [48-98]  0.22 [0.16-0.35]   346 [245-479]  Schneider et al. (2015) 
T2DM (n=61-64)   45 - 75   162 ± 31   2.28 ± 0.26   68 ± 4    Tsikas et al. (2015) 
Healthy subjects (n=241)  41 ± 15   1890 ± 1710 µM  0.89 ± 0.86 µM   1493 ± 1852  Chao et al. (2016) 
UTI patients (n=73) e  73 ± 14   360 ± 320 µM  15.2 ± 65 µM   23.7    Chao et al. (2016) 
Acromegaly (22 f/20 m)  46.1 ± 1.6  68.8 ± 69.6  0.13 ± 0.01   523   Present study 
 
Neonates, children and adolescents 
Preterm neonates (n=76)  23+6 to 36+1 weeks 283 ± 85   4.3 ± 10.7   210 ± 14   Buck et al. (2017) 
L-Arginine test (n=7) (t=0 h)  10 ± 2    132 [70-207]  0.34 [0.19-0.85]   359 [245-403]  Schneider et al. (2015) 
L-Arginine test (n=7) (t=2 h)     149 [105-190]  0.69 [0.44-0.74]   220 [166-256]  Schneider et al. (2015) 
Healthy (n=45)   11.1 ± 4.9  187 ± 335  0.46 ± 0.95   730 ± 591  Hörster et al. (2015) 
Healthy (n=95)   11.3 [8-13.3]  117 [85-164]  0.22 [0.13-0.37]   540 [324-962]  Carmann et al. (2015) 
DMD (n=54)   11.9 ± 4.8  230 ± 126  0.97 ± 1.10   424 ± 353  Hörster et al. (2015) 
T1DM untreated (n=10)  8.8 [4.4-11.2]  176 [149-390]  0.18 [0.11-0.33]   1341 [1117-1615]  Carmann et al. (2015) 
T1DM treated (n=92)  12.5 [10.5-15.4]  101 [72-158]  0.09 [0.06-0.17]   1173 [738-1481]   Carmann et al. (2015) 
Hypercholesterolemia (n=64)  11.5 ± 3.5  125 [99-164]  0.19 [0.10-0.48]   608 [211-1152]  Chobanyan-J. et al.  (2012) 
Normocholesterolemia (n=54) 11.9 ± 4.6  118 [78-154]  0.23 [0.15-0.45]   499 [274-890]  Chobanyan-J. et al.  (2012) 
Phenylketonuria (n=52)  12 ± 7   218 ± 218  1.7 ± 1.7    128 (ratio of the means) Kanzelmeyer et al. (2012) 
Healthy controls (n=46)  12 ± 7   280 ± 439  0.7 ± 1.2    400 (ratio of the means) Kanzelmeyer et al. (2012) 
FSGS (n=9)   11 ± 4   262 ± 419  3 ± 5    87 (ratio pgf the means) Lücke et al. (2008) 
Non-FSGS (n=11)   4 ± 3   174 ± 204  1.3 ± 1.5    134 (ratio of the means) Lücke et al. (2008) 
Healthy controls (n=9)  11 ± 5   421 ± 712  1.3 ± 2    324 (ratio of the means) Lücke et al. (2008) 
Healthy black boys (n=39)  7.3 ± 0.7   67 [60.5-92.8] f  0.26 [0.18-0.46]   483 ± 314 g  Present study 
Healthy white boys (n=41)  7.3 ± 0.8   94 [81.7-134]  0.25 [0.21-0.31]   314 ± 155  Present study 
  
Animals 
LEW.1AR1-iddm rat (healthy, n=5)    73.8 ± 8.4  0.24 ± 0.03   308 ± 10   Present study 
LEW.1AR1-iddm rat (T1DM, n=5)    139 ± 24   0.87 ± 0.32   198 ± 26   Present study 
APOE*3-Leiden.CETP mice (n=7)    88.4 [76-159]  0.80 [0.50-1.04]   155 [124-180]  Present study  
APOE*3-Leiden.CETP mice (n=9)    474 [371-613]  1.10 [0.75-1.45]   458 [318-557]  Present study  
________________________________________________________________________________________________________________ 
a Abbreviations: m, male; f, female. 
b Pre-operatively (baseline); c post-operatively, 40-60 min: d post-operatively: 60-240 min. 
e Hospitalized patients with urinary tract infections (UTI). 
f  P=0.0065, Mann-Whitney test, black vs. white boys for UNOxR. 
g  P=0.0007, Mann-Whitney test, black vs. white boys for urinary nitrate.  
ARG, L-arginine group; PLA, placebo group 
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Fig. S1. Relationship between UNOxR and (A) age or disease duration (B) in the T2DM 
patients of the DALI study (The DALI Study Group 2001) at baseline. Effect of a 30-
weeks (30) treatment with atorvastatin (AT) 10 mg/d (10), 80 mg/d (80) or placebo 
(PLA). This Figure was constructed with data reported in the Table 1 of a previous study 
(Tsikas et al. 2015). 
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Fig. S2. UNOxR in 10 overweight men upon ingestions of three different mealsThe meals 
differed with respect to the protein isolates (casein in meal C, whey protein in meal A, 
and -lactalbumin-enriched whey protein in meal L). Data are shown as mean±SEM. For 
more details see the main text. 
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Fig. S3. GC-MS chromatograms from analyses of spot urine samples collected before and 
after [15N]nitrite sodium and acetazolamide intake by a healthy female subject (age, 25 
years) (Tsikas et al. 2010b). The volunteer drank two times [15N]nitrite sodium dissolved 
in drinking water (0.31 µmol/kg each) and took once acetazolamide (5.4 mg/kg 
bodyweight). The first [15N]nitrite intake was ingested at the time point “zero” (0 h, 
panel A). U15NOxR is calculated by dividing the peak area ratio (PAR) of m/z 63 
5 
 
([15N]nitrate) to m/z 62 ([14N]nitrate) by the PAR of m/z 47 ([15N]nitrite) to m/z 46 
([14N]nitrite) (see Fig. 8A in the main text).  
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Fig. S4. Illustration of the UNOxR values for healthy and ill adults (A) and children (B) 
reported in the main text of the article (see Table 1). HC, healthy; OLT, patients with 
liver disease before orthotopic liver transplantation; HyperCh, hypercholesterolemia; 
DMD, Duchenne muscular dystrophy; PKU, phenylketonuria; FSGS, sporadic focal 
segmental glomerulosclerosis. 
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